These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 19136546

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW, CHOICE investigators.
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [Abstract] [Full Text] [Related]

  • 3. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG.
    Neurology; 2007 Aug 21; 69(8):785-9. PubMed ID: 17709711
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Spotlight on anti-CD25: daclizumab in MS.
    Schippling DS, Martin R.
    Int MS J; 2008 Sep 21; 15(3):94-8. PubMed ID: 18808743
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
    Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G, SELECT study investigators.
    Lancet; 2013 Jun 22; 381(9884):2167-75. PubMed ID: 23562009
    [Abstract] [Full Text] [Related]

  • 9. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.
    Sheridan JP, Zhang Y, Riester K, Tang MT, Efros L, Shi J, Harris J, Vexler V, Elkins JS.
    Mult Scler; 2011 Dec 22; 17(12):1441-8. PubMed ID: 21807759
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.
    Sheridan JP, Robinson RR, Rose JW.
    Expert Rev Clin Pharmacol; 2014 Jan 22; 7(1):9-19. PubMed ID: 24308792
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
    Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, McNeill M, Amaravadi L, Sweetser M, Elkins J, O'Neill G, SELECTION Study Investigators.
    Lancet Neurol; 2014 May 22; 13(5):472-81. PubMed ID: 24656609
    [Abstract] [Full Text] [Related]

  • 17. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.
    Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, Frank JA, Würfel J, Ohayon J, Waldmann TA, McFarland HF, Martin R.
    Proc Natl Acad Sci U S A; 2004 Jun 08; 101(23):8705-8. PubMed ID: 15161974
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
    Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R.
    Proc Natl Acad Sci U S A; 2006 Apr 11; 103(15):5941-6. PubMed ID: 16585503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.